Pascal Touchon, Atara Biotherapeutics CEO

Atara Bio­ther­a­peu­tic­s' stock drops near­ly 50% af­ter PhII tri­al fail in MS

Atara Bio­ther­a­peu­tics’ cell ther­a­py flunked a Phase II study in pro­gres­sive mul­ti­ple scle­ro­sis, miss­ing the pri­ma­ry end­point as well as flu­id and imag­ing bio­mark­ers, the com­pa­ny said Wednes­day.

The biotech will “sig­nif­i­cant­ly re­duce” its ex­pens­es for the pro­gram and in­stead put the mon­ey to­ward its al­lo­gene­ic CAR-T pipeline and its part­ner­ship with Pierre Fab­re, which the com­pa­ny said should ex­tend its cash run­way be­yond the third quar­ter of 2025.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.